Searchable abstracts of presentations at key conferences in endocrinology

ea0026p606 | Clinical case reports | ECE2011

Primary hypothyroidism due to sublingual thyroid associated with growth failure, hyperprolactinemia and pituitary enlargement

Loghin A , Florescu A , Moisii L , Stefanescu C , Galesanu C

Introduction: Thyroid tissue may be found anywhere along the course of thyroglossal duct. Sublingual thyroid is a rare type of ectopic thyroid tissue resulting from failure of the embryonic development and migration of the thyroid gland to its normal pre-laryngeal site, reaching between genio-hioid and mylohyiod muscles. In most cases, hypothyroidism develops due to inadequate hormon production. Hypothyroidism may produce pituitary enlargement secondary to thyrotroph hyperplas...

ea0029p99 | Adrenal cortex | ICEECE2012

Cushing’s disease – limitations and boundaries

Idriceanu J. , Preda C. , Galesanu C. , Ungureanu M. , Scripcariu V. , Vasiliu I. , Potorac I. , Popovici R. , Mogos V. , Vulpoi C.

Introduction: Cushing’s disease is the most frequent cause of hypercortisolism. Although the classical form is easy to diagnose, nonspecific features raise differential diagnosis problems. Severe forms are associated with high mortality, but subclinical hypercortisolism also has significant morbidity.Patients and methods: Retrospective study of Cushing’s disease evolution in 14 patients, diagnosed between 2000 and 2011 (11 women, 3 men, age at ...

ea0029p194 | Bone & Osteoporosis | ICEECE2012

Zoledronic acid treatment improve bone strenght parameters assessed by BMD

Galesanu C. , Loghin A. , Florescu A. , Lisnic N. , Aancute P. , Zaharia V.

Introduction: Bisphosphonates therapy is the standard of care in postmenopausal osteoporosis. In the HORIZON-RFT, annual i.v. Zoledronic acid (ZOL) 5 mg infusion significantly reduced the rate of new fractures by increased bone mineral density (BMD). We proposed to evaluate the effect of ZOL treatment in BMD change in a group of postmenopausal osteoporotic women assessed by DXA–BMD. We have proposed also to assess the adverse events of this treatment.<p class="abstext...

ea0029p394 | Clinical case reports - Pituitary/Adrenal | ICEECE2012

Giant macroprolactinoma: recidive after 12 years (case report)

Loghin A. , Florescu A. , Grozavu I. , Haba D. , Apostu L. , Galesanu C.

Introduction: Prolactinomas are rare in childhood and adolescence, representing a half of pituitary adenomas (1% of intracranial tumors); macroadenomas are more frequent than microadenomas. The signs and symptoms depend on age, sex, tumor size and prolactin level. Due to a higher frequency of macroadenomas in boys, they present more often neuro-ophthalmologic findings (impaired vision, headache)Case report: We present a case of 25-year-old pacient diagno...

ea0029p397 | Clinical case reports - Pituitary/Adrenal | ICEECE2012

Macroprolactinomas: therapy compliance (case report)

Florescu A. , Loghin A. , Grozavu I. , Haba D. , Apostu L. , Galesanu C.

Prolactinomas represent 60% of primary pituitary tumors, galactorrrhoea and menstrual disturbances beeing the most frequent clinical features in women. The mass effect of macroadenomas is expressed by headache, visual field defects and hypopituitarism. The aims of therapy are reduction of tumour size, prevention of tumour expansion and restoration of gonadal function. Dopamine agonists normalize prolactin secretion and reduce tumour size in 40% of patients with macroadenoma.</...